Medtronic NIM Vital Nerve Monitoring System Recall Issued After Injuries Reported

FDA determined a Medtronic device correction notice constituted a NIM Vital Nerve Monitoring System recall, following at least 10 reports of patient injuries.

Federal regulators indicate that a correction notice issued for the Medtronic NIM Vital Nerve Monitoring System constitutes a Class I medical device recall, since problems with the monitoring system may cause severe injury or death for patients.

The U.S. Food and Drug Administration (FDA) announced the Medtronic NIM Vital Nerve Monitoring System recall designation on August 6, following at least 10 reports of injuries that may have resulted when the devices failed to issue an alert when the probe is placed on a nerve.

The NIM Vital Nerve Monitoring System is used during surgery to locate, monitor, and stimulate the nerves in the skull and spine, which also connect the brain and spinal cord to the muscles and sensory cells.

The device is supposed to issue an electromyography (EMG) tone when the probe is placed on a nerve, to help doctors avoid any surgical nerve damage during proceedures. However, reports suggest that there have been a number of false negative responses associated with the device.

The FDA warns that if the devices fail to issue an EMG tone when the NIM probe is placed on a nerve, it could cause a doctor to incorrectly determine there is no risk to the nerve in the area. As a result, patients may face an increased risk of nerve damage, facial nerve damage, nerve weakening, and nerve paralysis. Although 10 adverse event reports have been linked to the false negative responses, no deaths have been identified to date.

Do You Know About...

Childhood Diabetes Lawsuits Against Junk Food Industry

Lawyers are now pursuing financial compensation for families of children diagnosed with Type II diabetes, fatty liver disease and other chronic illnesses caused by addictive and harmful substances in ultra-processed foods.

Learn More

Information about the problems were previously outlined in a correction notice issued by Medtronic in June, which was sent to affected customers.

A correction does not remove the devices from the market. Instead, Medtronic will slate the devices for a fix for the issues via a system update later. However, the FDA designated this a class I recall, the most serious type of recall because the device may cause serious injury or death if patients continue to use it without correction.

The recall includes NIM Vital Nerve Monitoring System models: NIM4CM01, NIM4CM01RF, NIM4CPB1, NIM4CPB1RF, and NIM4SWU143. Medtronic is deploying the NIM Vital System software version 1.5.4 to fix the issue and will contact customers for the fix when it is ready.

The FDA and Medtronic warned that medical facilities must be aware that using the devices may lead to the possibility of a false negative, where stimulation is applied but no EMG output is identified to the user.

Additionally, Medtronic indicates healthcare providers should follow protocols for patients who are currently being monitored with the NIM system to help reduce the risk of nerve injury from false negative readings. They should also use alternative monitoring, surgical skills, experience, and anatomical knowledge to prevent damage to the nerves if monitoring is compromised.

Customers in the U.S. with questions are urged to contact their Medtronic Representative or Medtronic Customer Quality at RS.JaxProductQuality@medtronic.com.

0 Comments

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court
Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (Posted today)

A federal judge has issued pretrial schedules for the first two BioZorb lawsuits to go before juries starting in September, calling for the parties to outline all the issues of contention, witnesses and facts to be presented during the bellwether early test cases.

Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week
Covidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (Posted 2 days ago)

A federal magistrate judge has accepted new deadlines for expert discovery in Covidien hernia mesh lawsuits, which will also result in the selection of a mediator by February 24, to shepherd the parties through settlement negotiations.